Expert Interview
Discussing the P2 acelERA BC study of Giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer and the AMEERA-3 Phase 2 study of amcenestrant in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Ticker(s): SNY, RHHBY, GILD, AZN, DSKYNInstitution: Private Practice (Kenneth R. Hoffman, MD, MPH and Associates)
- Medical Oncologist and Cancer Epidemiologist in practice for 38 years with clinical and academic experience.
- knowledgable about most immuno-oncology therapeutics in development and the use of bispecific antibodies.
- Treats patients with NSCLC, ES-SCLC, breast cancer, DLBCL and many other oncologic/hematologic malignancies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
